Background and Objectives Liquid plasma (LQP) stands out as an alternative to thawed plasma (TP) for emergent transfusions due to longer shelf life. We aim to measure fibrinogen, Protein C, Protein S, FV, FVII, and FVIII activity in LQP, quantify how these factors levels change in LQP during storage, and characterize how they compare in LQP to TP.

Materials and Methods Coagulation factor activities were measured on Days 15, 26, and 27 for LQP (n=26) and Day 5 for TP (n=24). Bayesian statistical modeling was used to compare coagulation factor activity and quantify changes in activity during storage.

Results Fibrinogen and Protein C activity in Day 26 LQP (LQP26) was comparable to Day 5 TP (TP5) with posterior mean activity of 252 mg/dL vs 247 mg/dL and 100.4% vs 111.3%, respectively. FV, FVII, and FVIII had slightly lower activity in LQP26 vs TP5 with posterior mean activities of 42.6% vs 58.4%, 55.0% vs 62.2%, and 48.8% vs 55.0%, respectively. Protein S in LQP26 was low with posterior mean activity of 28.0%, which was slightly less than half that of TP5 at 64.9%. From Day 15 to Day 26, FVII in LQP decreased at a rate of −3.49% per day whereas fibrinogen, Protein C, Protein S, FV, and FVIII activity in LQP remained relatively stable.

Conclusion Compared to TP5, LQP26 has comparable activities of fibrinogen, Protein C, FV, FVII, and FVII but lower activity of Protein S. LQP is a viable alternative for use in emergency transfusions and massive transfusion protocols.

Highlights

- Liquid plasma factor activities, with the exception of protein S, are comparable to thawed plasma in terms of emergency use with the advantage of extended shelf life.

- Liquid plasma has adequate fibrinogen and Protein C levels on the last day of expiration.

- Liquid plasma has ∼50% FV, FVII and FVIII levels on the last day of expiration, making it a sufficient replacement option to TP for active bleeding.

The authors have declared no competing interest.

Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T32HL007974-23. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board of Yale University waived ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The data supporting the findings of this study are publicly available and can be downloaded from github.com/edwardslee/liquidplasma